Cost‐effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria

The licensed dose for omalizumab within Europe for chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, and is based on the most effective dose identified in clinical trials. However, many patients require longer‐term treatment with omalizumab and there is limited guidance on how to manage t...

Descripción completa

Detalles Bibliográficos
Autores principales: Denman, Sarah, Smith, Helin, Arumugakani, Gururaj, Mistry, Anoop, Savic, Sinisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Concise Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826333/
https://www.ncbi.nlm.nih.gov/pubmed/35775857
http://dx.doi.org/10.1111/ced.15316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826333/
https://www.ncbi.nlm.nih.gov/pubmed/35775857
http://dx.doi.org/10.1111/ced.15316

Ejemplares similares